Cambridge Trust Company Decreased Adobe Systems (ADBE) Position by $5.19 Million as Valuation Rose; Eventide Asset Management Lowered Its Stake in Sage Therapeutics (Call) (SAGE) as Stock Value Declined

May 20, 2018 - By Marguerite Chambers

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Eventide Asset Management Llc decreased its stake in Sage Therapeutics Inc (Call) (SAGE) by 37.11% based on its latest 2017Q4 regulatory filing with the SEC. Eventide Asset Management Llc sold 59,000 shares as the company’s stock declined 6.84% with the market. The institutional investor held 100,000 shares of the health care company at the end of 2017Q4, valued at $16.47M, down from 159,000 at the end of the previous reported quarter. Eventide Asset Management Llc who had been investing in Sage Therapeutics Inc (Call) for a number of months, seems to be less bullish one the $7.64B market cap company. The stock decreased 0.79% or $1.3 during the last trading session, reaching $164.26. About 346,610 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since May 20, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.




Cambridge Trust Company decreased its stake in Adobe Systems Inc (ADBE) by 16.29% based on its latest 2017Q4 regulatory filing with the SEC. Cambridge Trust Company sold 29,648 shares as the company’s stock rose 22.17% while stock markets declined. The institutional investor held 152,360 shares of the prepackaged software company at the end of 2017Q4, valued at $26.70 million, down from 182,008 at the end of the previous reported quarter. Cambridge Trust Company who had been investing in Adobe Systems Inc for a number of months, seems to be less bullish one the $117.25 billion market cap company. The stock increased 0.52% or $1.24 during the last trading session, reaching $238.09. About 1.42M shares traded. Adobe Systems Incorporated (NASDAQ:ADBE) has risen 66.71% since May 20, 2017 and is uptrending. It has outperformed by 55.16% the S&P500.

More notable recent Sage Therapeutics, Inc. (NASDAQ:SAGE) news were published by: Seekingalpha.com which released: “Sage Therapeutics 2018 Q1 – Results – Earnings Call Slides” on May 03, 2018, also Businesswire.com with their article: “Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” published on May 03, 2018, Streetinsider.com published: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” on May 15, 2018. More interesting news about Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: Benzinga.com and their article: “Benzinga Pro’s 5 Stocks To Watch Today” published on April 23, 2018 as well as Bizjournals.com‘s news article titled: “Sage Therapeutics asks FDA to approve lead drug for postpartum depression” with publication date: April 23, 2018.

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 57 analyst reports since September 3, 2015 according to SRatingsIntel. Stifel Nicolaus initiated Sage Therapeutics, Inc. (NASDAQ:SAGE) on Monday, November 14 with “Buy” rating. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by BMO Capital Markets on Thursday, August 3. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, September 3 by JP Morgan. The firm has “Buy” rating given on Monday, November 13 by Canaccord Genuity. As per Thursday, June 23, the company rating was initiated by H.C. Wainwright. Canaccord Genuity maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Monday, March 26. Canaccord Genuity has “Buy” rating and $21000 target. The firm has “Buy” rating given on Thursday, November 9 by BMO Capital Markets. Stifel Nicolaus maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Tuesday, September 12. Stifel Nicolaus has “Buy” rating and $91.0 target. The company was upgraded on Tuesday, February 14 by Chardan Capital Markets. Cowen & Co maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Thursday, August 3 with “Buy” rating.

Eventide Asset Management Llc, which manages about $1.15B and $1.92B US Long portfolio, upped its stake in Kalvista Pharmaceuticals Inc by 313,000 shares to 709,000 shares, valued at $6.91M in 2017Q4, according to the filing. It also increased its holding in Pattern Energy Group Inc (NASDAQ:PEGI) by 129,500 shares in the quarter, for a total of 1.02 million shares, and has risen its stake in Kar Auction Svcs Inc (NYSE:KAR).

Investors sentiment increased to 1.49 in Q4 2017. Its up 0.28, from 1.21 in 2017Q3. It is positive, as 27 investors sold SAGE shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported. Metropolitan Life Ny stated it has 0.03% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Texas-based Hbk Invests Limited Partnership has invested 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Moreover, X Management Lc has 0% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). Tekla Capital Management Ltd accumulated 67,815 shares or 0.43% of the stock. Atika Capital Management Lc owns 6,000 shares. Bnp Paribas Arbitrage Sa reported 7,894 shares. Nicholas LP invested in 39,052 shares. Voloridge Investment Management Limited Liability Corporation holds 53,908 shares or 0.19% of its portfolio. 30,000 were accumulated by Sphera Funds. Eagle Asset Management reported 619,028 shares or 0.56% of all its holdings. Dubuque Savings Bank And owns 0.05% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 1,810 shares. Legal And General Grp Public Limited Liability Company accumulated 0% or 16,952 shares. Granite Point Capital Ltd Partnership accumulated 0.29% or 18,000 shares. Goldman Sachs Group Incorporated invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Jpmorgan Chase & has 0.03% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 787,307 shares.

Since December 14, 2017, it had 0 insider purchases, and 6 sales for $42.42 million activity. $10.00M worth of stock was sold by PAUL STEVEN M on Tuesday, March 6. Another trade for 60,000 shares valued at $9.57M was sold by Robichaud Albert. $4.02 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares were sold by IGUCHI KIMI. FRATES JAMES M also sold $1.08M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares. On Wednesday, January 10 Kanes Stephen sold $7.80 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) or 44,000 shares.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on August, 2. They expect $-1.87 EPS, up 0.53% or $0.01 from last year’s $-1.88 per share. After $-1.68 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.31% negative EPS growth.

Among 39 analysts covering Adobe Systems (NASDAQ:ADBE), 28 have Buy rating, 0 Sell and 11 Hold. Therefore 72% are positive. Adobe Systems had 157 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of Adobe Systems Incorporated (NASDAQ:ADBE) earned “Buy” rating by Rosenblatt on Wednesday, June 22. The firm has “Buy” rating given on Sunday, July 30 by RBC Capital Markets. The firm has “Buy” rating by Canaccord Genuity given on Thursday, December 14. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, June 20. Piper Jaffray maintained Adobe Systems Incorporated (NASDAQ:ADBE) on Monday, October 16 with “Buy” rating. Stifel Nicolaus maintained the shares of ADBE in report on Thursday, October 19 with “Buy” rating. The stock has “Neutral” rating by Goldman Sachs on Wednesday, September 21. Canaccord Genuity maintained it with “Buy” rating and $170 target in Wednesday, September 20 report. Credit Suisse upgraded Adobe Systems Incorporated (NASDAQ:ADBE) on Friday, March 24 to “Outperform” rating. The stock of Adobe Systems Incorporated (NASDAQ:ADBE) has “Buy” rating given on Monday, March 12 by Stifel Nicolaus.

Cambridge Trust Company, which manages about $1.58 billion US Long portfolio, upped its stake in Unilever Plc (NYSE:UL) by 64,800 shares to 127,905 shares, valued at $7.08M in 2017Q4, according to the filing. It also increased its holding in Blackrock Inc (NYSE:BLK) by 634 shares in the quarter, for a total of 39,814 shares, and has risen its stake in Unitedhealth Group Inc (NYSE:UNH).

Analysts await Adobe Systems Incorporated (NASDAQ:ADBE) to report earnings on June, 19. They expect $1.25 earnings per share, up 54.32% or $0.44 from last year’s $0.81 per share. ADBE’s profit will be $615.59M for 47.62 P/E if the $1.25 EPS becomes a reality. After $1.28 actual earnings per share reported by Adobe Systems Incorporated for the previous quarter, Wall Street now forecasts -2.34% negative EPS growth.

Since December 13, 2017, it had 1 buying transaction, and 17 sales for $87.77 million activity. GESCHKE CHARLES M sold $3.59 million worth of stock or 16,000 shares. Lewnes Ann also sold $680,503 worth of Adobe Systems Incorporated (NASDAQ:ADBE) shares. Another trade for 18,410 shares valued at $3.63M was sold by Rencher Bradley. On Wednesday, January 24 the insider NARAYEN SHANTANU sold $32.66 million. Shares for $10.21 million were sold by GARRETT MARK. Another trade for 18,079 shares valued at $3.51M was made by DILLON MICHAEL A on Monday, February 5.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.